NCT04172532 2026-03-18
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
24 trialsNCT06958328 2026-02-02
LAP100
NRG Oncology
Phase 3 Recruiting
NCT04484909 2025-10-27
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT06050317 2025-07-22
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT04098432 2024-09-23
CA209-9KH
University Hospital Hradec Kralove
Phase 1/2 Completed
NCT05088889 2023-11-28
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
Sheba Medical Center
Phase 1 Unknown
NCT04050085 2023-08-01
SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
University of California, Davis
Phase 1 Completed
NCT05399394 2022-06-01
FOLRT
Campus Bio-Medico University
Phase 2 Unknown
NCT03374293 2021-02-10
Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer
Hangzhou Cancer Hospital
Phase 2 Unknown
NCT00026104 2020-10-30
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00114179 2020-10-30
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02910882 2019-04-11
HALO-IST
Scripps Health
Phase 2 Terminated
NCT01534637 2018-08-15
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00463840 2017-12-05
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
NYU Langone Health
Phase 1/2 Terminated
NCT01893294 2017-03-22
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
Mayo Clinic
Phase 1 Completed
NCT02984501 2016-12-07
Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer
Campus Bio-Medico University
Phase 2 Completed
NCT00456599 2015-12-03
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00660699 2015-05-27
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
Washington University School of Medicine
Phase 2 Completed
NCT02159248 2015-04-28
Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Orlando Health, Inc.
Phase 1 Withdrawn
NCT01130701 2015-03-17
PMABIIS
University of Massachusetts, Worcester
Phase 2 Withdrawn
NCT00305877 2014-05-21
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00096070 2013-07-16
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00063947 2013-06-04
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed